@article{evrard:hal-03102304,
TITLE = {PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab $\pm$ Tremelimumab in second-line of patients with advanced gastric cancer},
AUTHOR = {Evrard, Camille and Louvet, Christophe and Hajbi, Farid El and Fiore, Fr{\'e}d{\'e}ric Di and Malicot, Karine Le and Aparicio, Thomas and Bouch{\'e},
Olivier and Laurent-Puig, Pierre and Bibeau, Fr{\'e}d{\'e}ric and Lecomte, Thierry and Li{\`e}vre, Astrid and Guimbaud, Rosine and Kim, Stefano and Zaanan, Aziz and Sokol, Harry and Chibaudel, Benoist and Desrame, J{\'e}rome and Pierre, Sabrina and Gonzalez, Daniel and Lepage, Come and Tougeron, David},
URL = {https://hal.science/hal-03102304},
JOURNAL = {Digestive and Liver Disease},
PUBLISHER = {Elsevier},
VOLUME = {53},
NUMBER = {4},
PAGES = {420-426},
YEAR = {2021},
MONTH = Apr, DOI = {10.1016/j.dld.2020.11.036},
KEYWORDS = {Adenocarcinoma ; Chemotherapy ; Gastric cancer ; Immune checkpoint inhibitors},
PDF = {https://hal.science/hal-03102304/file/Evrard%20et%20al%20-%202021%20-%20PRODIGE%2059-DURIGAST%20trial%20-CLEAN%20final.pdf},
HAL_ID = {hal-03102304},
HAL_VERSION = {v1},
}